Susquehanna International Group’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-20,200
Closed -$788K 13314
2024
Q2
$788K Sell
20,200
-2,600
-11% -$71.5K ﹤0.01% 7147
2024
Q1
$494K Sell
22,800
-8,800
-28% -$196K ﹤0.01% 8544
2023
Q4
$814K Buy
31,600
+9,500
+43% +$178K ﹤0.01% 7485
2023
Q3
$404K Buy
+22,100
New +$382K ﹤0.01% 8730
2022
Q1
Sell
-32,300
Closed -$800K 14193
2021
Q4
$800K Buy
+32,300
New +$649K ﹤0.01% 7886

Other funds holding CALT

Susquehanna International Group's CALT Position: Q3 2024 in Review

Susquehanna International Group sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q3 2024, closing a stake of 5,397 shares — an estimated $210K sold.

Susquehanna International Group first reported a position in CALT in Q4 2023 and held it in 3 quarters. The position peaked at $243K in Q4 2023. 5 funds tracked by Wall St. Rank hold CALT as of Q3 2024.

  • Susquehanna International Group reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q3 2024 after selling out during the quarter.
  • Susquehanna International Group sold 5,397 Calliditas Therapeutics AB American Depositary Shares shares in Q3 2024, an estimated $210K.
  • Susquehanna International Group first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q4 2023 and held it in 3 quarters.
  • Susquehanna International Group's Calliditas Therapeutics AB American Depositary Shares position peaked at $243K in Q4 2023.
  • 5 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q3 2024.

Based on Susquehanna International Group's 13F filing for Q3 2024, filed 14 Nov 2024.